Vincerx Pharma, Inc. (NASDAQ:VINC) Short Interest Update

Vincerx Pharma, Inc. (NASDAQ:VINC) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totalling 4,710,000 shares, a growth of 1,022.5% from the December 15th total of 419,600 shares. Based on an average trading volume of 6,840,000 shares, the short-interest ratio is presently 0.7 days.

Vincerx Pharma Trading Down 1.8 %

NASDAQ VINC opened at $0.17 on Wednesday. The company’s 50-day moving average price is $0.24 and its 200-day moving average price is $0.49. The stock has a market cap of $5.64 million, a PE ratio of -0.16 and a beta of 1.48. Vincerx Pharma has a 12 month low of $0.16 and a 12 month high of $9.37.

Wall Street Analysts Forecast Growth

Separately, Leerink Partners cut their price target on shares of Vincerx Pharma from $4.00 to $2.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vincerx Pharma stock. Marshall Wace LLP boosted its holdings in shares of Vincerx Pharma, Inc. (NASDAQ:VINC) by 359.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 328,533 shares of the company’s stock after acquiring an additional 256,967 shares during the period. Marshall Wace LLP owned about 1.11% of Vincerx Pharma worth $266,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 44.02% of the stock is currently owned by institutional investors and hedge funds.

About Vincerx Pharma

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.